NASDAQ : KRON
Kronos Bio, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.88 USD (At close: Jun 20, 2025) · Market cap 53.73M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | n/a |
| Enterprise Value | n/a |
Dates
| Measure | Value |
|---|
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 60.97M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 12.93 |
| Quick Ratio | 12.66 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -59.49% |
| Return on Assets (ROA) | -21.73% |
| Return on Invested Capital (ROIC) | -23.57% |
| Return on Capital Employed (ROCE) | -50.47% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $919,200 |
| Profits Per Employee | -$6.45M |
| Employee Count | 10 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.64 |
| 52-Week Price Change | -12.87% |
| 50-Day Moving Average | 0.79 |
| 200-Day Moving Average | 0.91 |
| Relative Strength Index (RSI) | 65.76 |
| Average Volume (20 Days) | 1,367,356 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 754,265 |
| Short Previous Month | 547,885 |
| Short % of Shares Out | 1.24% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.60 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 9.19M |
| Gross Profit | 9.19M |
| Operating Income | -50.60M |
| Pretax Income | -64.49M |
| Net Income | -64.49M |
| EBITDA | -49.14M |
| EBIT | -50.60M |
| Loss Per Share | -$1.07 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 99.73M |
| Total Debt | 24.09M |
| Net Cash | 75.65M |
| Net Cash Per Share | $1.24 |
| Equity (Book Value) | 79.81M |
| Book Value Per Share | 1.31 |
| Working Capital | 93.99M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -54.38M |
| Capital Expenditures | 3,000 |
| Depreciation & Amortization | 1.46M |
| Net Borrowing | n/a |
| Free Cash Flow | -54.38M |
| FCF Per Share | -$0.89 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -550.46% |
| Pretax Margin | -701.53% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.52% |
| Shareholder Yield | -3.52% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 15.06% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -6.94 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |